Asia Pacific Pharmaceutical Cdmo Market Size & Outlook
Global Market
Related Markets
Asia Pacific pharmaceutical cdmo market highlights
- The Asia Pacific pharmaceutical cdmo market generated a revenue of USD 58,933.1 million in 2024.
- The market is expected to grow at a CAGR of 8% from 2025 to 2033.
- In terms of segment, api was the largest revenue generating product in 2024.
- API is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, China is expected to register the highest CAGR from 2025 to 2033.
Asia Pacific data book summary
| Market revenue in 2024 | USD 58,933.1 million |
| Market revenue in 2033 | USD 118,245.4 million |
| Growth rate | 8% (CAGR from 2025 to 2033) |
| Largest segment | Api |
| Fastest growing segment | API |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | API, Drug Product |
| Key market players worldwide | Lonza Group Ltd, Thermo Fisher Scientific Inc, Labcorp Holdings Inc, Catalent Inc, Wuxi AppTec Co Ltd, Siegfried Holding AG, Nipro Corp, Piramal Pharma Solutions, Recipharm Venture Fund, CordenPharma, Cambrex, Bushu Pharmaceuticals, Seqens |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 37.9% of the global pharmaceutical cdmo market in 2024.
- Globally, Asia Pacific is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 118,245.4 million by 2033.
Asia Pacific held the largest market share of 37.64% and is expected to maintain this dominance over the forecast period. This growth can be attributed to various factors, such as improved social insurance schemes and constantly improving economic conditions in the region.
Which allow patients to pay out-of-pocket pharmaceutical costs. In recent years, countries such as Singapore, China, and India have been observed to be major players in the pharmaceutical industry owing to their expanding manufacturing capabilities.
In addition, in the past decade, the manufacturing of pharmaceutical products has been outsourced to Asian countries, including India & China. Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies.
No credit card required*
Publish Date: Sep 15, 2025
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Three ways to get this data
Subscribe to the databook, customize it, or ask a question.Horizon Databook
Unlock every chart on this page and get dashboard access
- Statistics1.2M+ across all markets
- Databooks30K+ global, 120K+ country
- Companies200K+ profiles
- ExportPDF, Dashboard, XLS & PNG, licensed to cite
Customize it
Customize data as per your requirement
- AddCountries, segments, years
- RecutTo your product definition
- ExtendCompany-level detail
- OrA bespoke databook
- Turnaround5–10 working days
Ask Prism AI
A cited answer in seconds
- Corpus30,000 studies, 1.2M points
- ScopeAll markets, not just this
- CitationTraced to report & table
- HonestySays "not covered" if so
- SpeedSeconds, not days
Pharmaceutical CDMO Market Scope
Pharmaceutical CDMO Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Lonza Group Ltd | View profile | 18,000 | Muenchensteinerstrasse 38, Basel, Switzerland, CH-4002 | www.lonza.com |
| Thermo Fisher Scientific Inc | View profile | 122,000 | 168 Third Avenue, Waltham, MA, United States, 02451 | www.thermofisher.com |
| Labcorp Holdings Inc | View profile | 67,000 | 358 South Main Street, Burlington, NC, United States, 27215 | www.labcorp.com |
| Nipro Corp | View profile | 39,713 | 3-9-3 Honjo-Nishi Kita-ku, Osaka, Japan, 531-8510 | www.nipro.co.jp |
| Wuxi AppTec Co Ltd | View profile | 41,116 | 288 Fute Zhong Road, Waigaoqiao Free Trade Zone, Shanghai, China, People's Republic of, 200131 | www.wuxiapptec.com |
| Catalent Inc | View profile | 17,219 | 14 Schoolhouse Road, Somerset, NJ, United States, 08873 | www.catalent.com |
| Siegfried Holding AG | View profile | 4,180 | Untere Bruehlstrasse 4, Zofingen, Switzerland, CH-4800 | www.siegfried.ch |
| Piramal Pharma Solutions | View profile | 1001-5000 | Riverview, Michigan, United States, North America | www.piramalpharmasolutions.com/ |
| CordenPharma | View profile | 5001-10000 | Plankstadt, Baden-Wurttemberg, Germany, Europe | cordenpharma.com |
| Cambrex | View profile | 1001-5000 | East Rutherford, New Jersey, United States, North America | www.cambrex.com |
Asia Pacific Pharmaceutical CDMO Market Outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to Pharmaceutical CDMO Market Outlook will help companies and investors design strategic landscapes.
Api was the largest segment with a revenue share of 81.44% in 2024.
Horizon Databook has segmented the Asia Pacific pharmaceutical cdmo market based on api, drug product covering the revenue growth of each sub-segment from 2021 to 2033.
Asia Pacific held the largest market share of 37.64% and is expected to maintain this dominance over the forecast period. This growth can be attributed to various factors, such as improved social insurance schemes and constantly improving economic conditions in the region.
Which allow patients to pay out-of-pocket pharmaceutical costs. In recent years, countries such as Singapore, China, and India have been observed to be major players in the pharmaceutical industry owing to their expanding manufacturing capabilities.
In addition, in the past decade, the manufacturing of pharmaceutical products has been outsourced to Asian countries, including India & China. Furthermore, the availability of a large number of potential study subjects has driven several pharmaceutical companies.
- Asia Pacific Pharmaceutical Cdmo Market Product Outlook (Revenue, USD Million , 2021-2033)
- API
- Drug Product
- Asia Pacific Pharmaceutical Cdmo Market Work Flow Outlook (Revenue, USD Million , 2021-2033)
- Clinical
- Commercial
- Asia Pacific Pharmaceutical Cdmo Market Application Outlook (Revenue, USD Million , 2021-2033)
- Oncology
- Infectious Diseases
- Neurological Disorders
- Cardiovascular Diseases
- Metabolic Disorders
- Autoimmune Diseases
- Respiratory Diseases
- Ophthalmology
- Gastrointestinal Disorders
- Hormonal Disorders
- Hematological Disorders
- Others
- Asia Pacific Pharmaceutical Cdmo Market Service Outlook (Revenue, USD Million , 2021-2033)
- Contract Development
- Contract Manufacturing
- Packaging
- Quality Control and Assurance
- Others
- Asia Pacific Pharmaceutical Cdmo Market End Use Outlook (Revenue, USD Million , 2021-2033)
- Pharmaceutical Companies
- Biotechnology Companies
- Others
Reasons to subscribe to Pharmaceutical CDMO Market Outlook databook
- Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
- Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
- Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
- Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
- Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Pharmaceutical CDMO Market Outlook databook
- Our clientele includes a mix of Pharmaceutical CDMO Market Outlook companies, investment firms, advisory firms & academic institutions.
- 30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
- Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
- The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Asia Pacific Pharmaceutical CDMO Market Outlook, including forecasts for subscribers. This continent databook contains high-level insights into Asia Pacific Pharmaceutical CDMO Market Outlook from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Asia Pacific Pharmaceutical Cdmo Market, 2021-2033 (US$M)
Asia Pacific Product - Pharmaceutical Cdmo Market Statistics, 2024 - 2033 (US$M)
